CAR-T细胞疗法后继发性血液系统肿瘤的罕见性与风险 - Suppr

Rarity & Risk of Secondary Hematologic Neoplasms after CAR T-cell Therapies.

作者信息

Hamilton Mark P, Alizadeh Ash A

机构信息

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Center for Cancer Cell Therapy, Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA; Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA.

Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA; Stanford Cancer Institute, Stanford University, Stanford, CA, 94305, USA; Institute for Stem Cell Biology and Regenerative Medicine, Stanford University, Stanford, CA, 94305, USA.